$ACET
Adicet Bio, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018021129 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.270M $640.0K
YoY Change 254.69%
% of Gross Profit
Research & Development $11.85M $3.420M
YoY Change 246.35%
% of Gross Profit
Depreciation & Amortization $20.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $14.11M $4.060M
YoY Change 247.61%
Operating Profit -$14.11M -$4.057M
YoY Change 247.87%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $522.0K $0.00
YoY Change
Pretax Income -$13.59M -$4.060M
YoY Change 234.75%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.59M -$4.057M
YoY Change 235.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.389M -$1.012M
COMMON SHARES
Basic Shares Outstanding 28.05M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.9M
YoY Change
Cash & Equivalents $51.35M $3.310M
Short-Term Investments $74.60M
Other Short-Term Assets $2.500M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $128.4M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K
YoY Change
Total Long-Term Assets $400.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $128.4M
Total Long-Term Assets $400.0K
Total Assets $128.8M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.500M
YoY Change
Accrued Expenses $6.600M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.60M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $25.00K
YoY Change
Total Long-Term Liabilities $25.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.60M
Total Long-Term Liabilities $25.00K
Total Liabilities $11.60M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $117.2M
YoY Change
Total Liabilities & Shareholders Equity $128.8M
YoY Change

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$13.59M -$4.057M
YoY Change 235.0%
Depreciation, Depletion And Amortization $20.00K $0.00
YoY Change
Cash From Operating Activities -$9.790M -$1.850M
YoY Change 429.19%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$50.00K
YoY Change -60.0%
Acquisitions
YoY Change
Other Investing Activities -$74.54M $0.00
YoY Change
Cash From Investing Activities -$74.57M -$50.00K
YoY Change 149040.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.210M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.790M -1.850M
Cash From Investing Activities -74.57M -50.00K
Cash From Financing Activities 0.000 5.210M
Net Change In Cash -84.36M 3.310M
YoY Change -2648.64%
FREE CASH FLOW
Cash From Operating Activities -$9.790M -$1.850M
Capital Expenditures -$20.00K -$50.00K
Free Cash Flow -$9.770M -$1.800M
YoY Change 442.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
74570000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
792000
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
929000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
84000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
55154000
CY2018Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
84000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39000
CY2017Q4 us-gaap Assets
Assets
55193000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1515000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3987000
CY2018Q2 us-gaap Customer Advances Current
CustomerAdvancesCurrent
500000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5502000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
25000
CY2017Q4 us-gaap Liabilities
Liabilities
5502000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1849000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
117164000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128780000
CY2018Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
37000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
32000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28048315
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5659089
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28048315
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5659089
CY2018Q2 torc Common Stock Shares Vested
CommonStockSharesVested
28046315
CY2017Q4 torc Common Stock Shares Vested
CommonStockSharesVested
4562640
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19951000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2268000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
637000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4362000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
14113000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
4057000
us-gaap Costs And Expenses
CostsAndExpenses
24313000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14113000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4057000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
522000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
863000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23450000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7414000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13591000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-4057000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28046315
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4302231
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4057000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23480000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
57000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000
us-gaap Share Based Compensation
ShareBasedCompensation
1583000
us-gaap Share Based Compensation
ShareBasedCompensation
210000
torc Expense Related To Acquisition Of Intellectual Property
ExpenseRelatedToAcquisitionOfIntellectualProperty
3157000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
84000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1573000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
532000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3119000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2247000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2819000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
193000
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
500000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
25000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17087000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2139000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
304000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
74543000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74847000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
5500000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
89938000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89938000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5500000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1996000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3310000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3310000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
81620000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;font-style:normal;"> </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities, as of the date of the condensed consolidated financial statements, and the reported amounts of any expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities, income taxes, and stock-based compensation expense. Management bases its estimates on historical experience, and on various other market-specific relevant assumptions that management believes to be reasonable, under the circumstances. Actual results may differ from those estimates or assumptions. </p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-07-05
CY2018Q1 torc Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2018-01-12
CY2018Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-1.2804
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
125900000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2018Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
900000
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
74600000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
74570000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2018Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
74600000
CY2018Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
74570000
CY2018Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
74570000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
360000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5000
us-gaap Depreciation
Depreciation
31000
us-gaap Depreciation
Depreciation
0
CY2018Q2 torc Accrued Wages Bonuses Vacation And Payroll Taxes Current
AccruedWagesBonusesVacationAndPayrollTaxesCurrent
497000
CY2017Q4 torc Accrued Wages Bonuses Vacation And Payroll Taxes Current
AccruedWagesBonusesVacationAndPayrollTaxesCurrent
394000
CY2018Q2 torc Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5866000
CY2017Q4 torc Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3250000
CY2017Q4 torc Deferred Offering Costs Current
DeferredOfferingCostsCurrent
238000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
205000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105000
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20320667
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2780278
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17736568
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-1.2804
CY2018Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.781
CY2018Q2 us-gaap Litigation Reserve
LitigationReserve
0
CY2017Q4 us-gaap Litigation Reserve
LitigationReserve
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
752850
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4244598

Files In Submission

Name View Source Status
0001564590-18-021129-index-headers.html Edgar Link pending
0001564590-18-021129-index.html Edgar Link pending
0001564590-18-021129.txt Edgar Link pending
0001564590-18-021129-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
torc-10q_20180630.htm Edgar Link pending
torc-20180630.xml Edgar Link completed
torc-20180630.xsd Edgar Link pending
torc-20180630_cal.xml Edgar Link unprocessable
torc-20180630_def.xml Edgar Link unprocessable
torc-20180630_lab.xml Edgar Link unprocessable
torc-20180630_pre.xml Edgar Link unprocessable
torc-ex311_6.htm Edgar Link pending
torc-ex312_7.htm Edgar Link pending
torc-ex321_8.htm Edgar Link pending